Similar tumor growth patterns were observed in the E0771 breast cancer model when AccuTOX® was combined with anti-PD-1 (orange line) or anti-CD47 (yellow line—Fig. 2D) with a final survival rate of 60 and 100% respectively (Fig. 2E). Here, CD47 is linked to breast carcinoma.